Gilead Increases NASH Emphasis With Pickup Of Nimbus ACC Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Nimbus Therapeutics gets $400m up front in exchange for its ACC inhibitor program for NASH and HCC, giving Gilead four different mechanisms in a field of high unmet medical need.